The signature of liver cancer in immune cells DNA methylation
Background: The idea that changes to the host immune system are critical for cancer progression was proposed a century ago and recently regained experimental support.
Results: Herein, the hypothesis that hepatocellular carcinoma (HCC) leaves a molecular signature in the host peripheral immune system was tested by profiling DNA methylation in peripheral blood mononuclear cells (PBMC) and T cells from a discovery cohort (n = 69) of healthy controls, chronic hepatitis, and HCC using Illumina 450K platform and was validated in two validation sets (n = 80 and n = 48) using pyrosequencing.
Conclusions: The study reveals a broad signature of hepatocellular carcinoma in PBMC and T cells DNA methylation which discriminates early HCC stage from chronic hepatitis B and C and healthy controls, intensifies with progression of HCC, and is highly enriched in immune function-related genes such as PD-1, a current cancer immunotherapy target. These data also support the feasibility of using these profiles for early detection of HCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Clinical epigenetics - 10(2018) vom: 16., Seite 8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yonghong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DNA methylation |
|---|
| Anmerkungen: |
Date Completed 27.02.2019 Date Revised 27.02.2019 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13148-017-0436-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM280360428 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM280360428 | ||
| 003 | DE-627 | ||
| 005 | 20231225025146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13148-017-0436-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0934.xml |
| 035 | |a (DE-627)NLM280360428 | ||
| 035 | |a (NLM)29375724 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yonghong |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The signature of liver cancer in immune cells DNA methylation |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2019 | ||
| 500 | |a Date Revised 27.02.2019 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: The idea that changes to the host immune system are critical for cancer progression was proposed a century ago and recently regained experimental support | ||
| 520 | |a Results: Herein, the hypothesis that hepatocellular carcinoma (HCC) leaves a molecular signature in the host peripheral immune system was tested by profiling DNA methylation in peripheral blood mononuclear cells (PBMC) and T cells from a discovery cohort (n = 69) of healthy controls, chronic hepatitis, and HCC using Illumina 450K platform and was validated in two validation sets (n = 80 and n = 48) using pyrosequencing | ||
| 520 | |a Conclusions: The study reveals a broad signature of hepatocellular carcinoma in PBMC and T cells DNA methylation which discriminates early HCC stage from chronic hepatitis B and C and healthy controls, intensifies with progression of HCC, and is highly enriched in immune function-related genes such as PD-1, a current cancer immunotherapy target. These data also support the feasibility of using these profiles for early detection of HCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Immune functions | |
| 650 | 4 | |a Peripheral white blood cells | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Petropoulos, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jinhua |e verfasserin |4 aut | |
| 700 | 1 | |a Cheishvili, David |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Rudy |e verfasserin |4 aut | |
| 700 | 1 | |a Dymov, Sergiy |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Kang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Szyf, Moshe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical epigenetics |d 2010 |g 10(2018) vom: 16., Seite 8 |w (DE-627)NLM205276547 |x 1868-7083 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2018 |g day:16 |g pages:8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13148-017-0436-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2018 |b 16 |h 8 | ||